These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30012755)

  • 1. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.
    Kidd JM; Abdelraouf K; Asempa TE; Humphries RM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
    Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic
    Abbott IJ; van Gorp E; van der Meijden A; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.
    Werth BJ; Steed ME; Ireland CE; Tran TT; Nonejuie P; Murray BE; Rose WE; Sakoulas G; Pogliano J; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5253-61. PubMed ID: 24957825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
    Luther MK; Arvanitis M; Mylonakis E; LaPlante KL
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4612-20. PubMed ID: 24867993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacodynamic activity of daptomycin.
    Safdar N; Andes D; Craig WA
    Antimicrob Agents Chemother; 2004 Jan; 48(1):63-8. PubMed ID: 14693519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
    Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.
    Kebriaei R; Rice SA; Singh KV; Stamper KC; Dinh AQ; Rios R; Diaz L; Murray BE; Munita JM; Tran TT; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760141
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimicrobial susceptibility of enterococci recovered from healthy cattle, pigs and chickens in nine EU countries (EASSA Study) to critically important antibiotics.
    de Jong A; Simjee S; Garch FE; Moyaert H; Rose M; Youala M; Dry M;
    Vet Microbiol; 2018 Mar; 216():168-175. PubMed ID: 29519512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
    Griffith DC; Rodriguez D; Corcoran E; Dudley MN
    Antimicrob Agents Chemother; 2008 Jan; 52(1):244-7. PubMed ID: 17954697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A High Daptomycin Dose Is Associated with Better Bacterial Clearance in Infections Caused by Vancomycin-Resistant Enterococcus faecium Regardless of Daptomycin Minimum Inhibitory Concentration in a Rat Infective Endocarditis Model.
    Wang JT; Yang CJ; Yang JL; Lin SW; Chuang YC; Sheng WH; Chen YC; Chang SC
    Microbiol Spectr; 2022 Oct; 10(5):e0255122. PubMed ID: 36190402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
    J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of Enterococcus faecalis and Enterococcus faecium in Various Clinical Infections: Detection of Their Drug Resistance and Virulence Determinants.
    Jahansepas A; Aghazadeh M; Rezaee MA; Hasani A; Sharifi Y; Aghazadeh T; Mardaneh J
    Microb Drug Resist; 2018; 24(1):76-82. PubMed ID: 28525287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis.
    Reissier S; Saleh-Mghir A; Guerin F; Massias L; Ghout I; Sinel C; Cattoir V; Cremieux AC
    J Antimicrob Chemother; 2018 Apr; 73(4):981-986. PubMed ID: 29329389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.